Editas Medicine, Inc.EDIT
NASDAQ • Healthcare
$2.88
P/E
—
PEG
—
FCF Yield
—
Rev Growth YoY
-39.2% YoY
Gross Margin
82.9%
Health Score
3/10
D/E Ratio
2.81
Confidence
LOW
Business Snapshot
Editas Medicine is a clinical-stage biotechnology company focused on developing CRISPR-based gene editing therapies for inherited diseases. The company operates in the competitive gene editing space, positioning itself as a challenger to more advanced peers like CRISPR Therapeutics and Vertex Pharmaceuticals. With a market capitalisation undisclosed and trailing twelve-month revenue of only $38.69M, it falls into the micro-cap tier with minimal commercial revenue and heavy reliance on partnership funding. The defining characteristic of Editas is its early-stage, pre-revenue pipeline — the company has yet to bring a product to market and burns cash aggressively to fund research and development.
Financial Health
Gross margin stands at 82.9%, down from 100.0% in the prior year, indicating a shift in revenue mix or cost structure. Net margin is reported at -281.6% — note this figure may be distorted due to a one-time item or data anomaly; the underlying reality is deep operating losses...
Risk Assessment
- REVENUE DECELERATION — Revenue declined 39.2% year-over-year and an even steeper 88.6% quarter-over-quarter, indicating rapid deterioration in the top line.
- DEBT — Debt/equity of 2.81x is high for a pre-commercial biotech, increasing financial fragility and reliance on external financing.
- FCF / CASH BURN — Free cash flow of -$165.85M dwarfs TTM revenue of $38.69M, implying the company is burning cash at an alarming rate with no near-term path to self-funding.
- VALUATION — Price/sales of 7.48x is rich for a company with -39.2% revenue growth and no earnings; the premium over any intrinsic value anchor is not supported by fundamentals.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- 52-WEEK POSITION — The current price of $2.88 is below the 52-week midpoint of $2.94 and well below the high of $4.537, indicating the stock remains in a downtrend relative to its recent highs....